Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma

Condition:   Esophageal Carcinoma
Intervention:   Drug: Pertuzumab, trastuzumab
Sponsors:   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);   Roche Pharma AG
Recruiting - verified July 2016

from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/2ah2CDz
via IFTTT